Please assess the completion status of the following clinical trial:

Trial Title: Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the exocrine pancreas~* Metastatic disease~* Documented disease progression after prior gemcitabine based therapy~* KPS \>/= 70~* Adequate bone marrow function~* Adequate hepatic function~* Adequate renal function~Exclusion Criteria:~* Active CNS metastasis~* Clinically significant GI disorders~* Severe arterial thromboembolic events less than 6 months before inclusion~* NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure~* Active infection or uncontrolled fever~* Pregnant or breast feeding patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MM-398 (Type: EXPERIMENTAL): MM-398 120 mg/m2 Q3W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 120 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 100 mg/ m2 of irinotecan free base.
- 5 Fluorouracil and Leucovorin IV (Type: ACTIVE_COMPARATOR): 5 Fluorouracil and Leucovorin IV
- MM-398, 5-FU and Leucovorin (Type: EXPERIMENTAL): MM-398 80 mg/m2, 5-FU and Leucovorin Q2W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 80 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 70 mg/ m2 of irinotecan free base.

Based on this trial design, predict the completion outcome and termination type (if applicable).